BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 37759322)

  • 21. Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience.
    Galletti C; Ragusa M; Sireci F; Ciodaro F; Barbieri MA; Giunta G; Grigaliute E; Immordino A; Lorusso F; Dispenza F; Freni F; Galletti F; Gallina S; La Mantia I; Galletti B
    Am J Otolaryngol; 2024; 45(1):104106. PubMed ID: 37948824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is generative pre-trained transformer artificial intelligence (Chat-GPT) a reliable tool for guidelines synthesis? A preliminary evaluation for biologic CRSwNP therapy.
    Maniaci A; Saibene AM; Calvo-Henriquez C; Vaira L; Radulesco T; Michel J; Chiesa-Estomba C; Sowerby L; Lobo Duro D; Mayo-Yanez M; Maza-Solano J; Lechien JR; La Mantia I; Cocuzza S
    Eur Arch Otorhinolaryngol; 2024 Apr; 281(4):2167-2173. PubMed ID: 38329526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps.
    Patel GB; Peters AT
    Ear Nose Throat J; 2021 Jan; 100(1):44-47. PubMed ID: 33035132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis.
    Peters AT; Wagenmann M; Bernstein JA; Khan AH; Nash S; Jacob-Nara JA; Siddiqui S; Rowe PJ; Deniz Y
    Allergy Asthma Proc; 2023 Jul; 44(4):265-274. PubMed ID: 37480206
    [No Abstract]   [Full Text] [Related]  

  • 25. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52.
    Bachert C; Khan AH; Lee SE; Hopkins C; Peters AT; Fokkens W; Praestgaard A; Radwan A; Nash S; Jacob-Nara JA; Deniz Y; Rowe PJ
    Int Forum Allergy Rhinol; 2024 Mar; 14(3):668-678. PubMed ID: 37548085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective study on the efficacy of dupilumab in chronic rhinosinusitis with type 2 inflammation.
    Trimarchi M; Vinciguerra A; Rampi A; Tanzini U; Nonis A; Yacoub MR; Bussi M
    Acta Otorhinolaryngol Ital; 2022 Dec; 42(6):538-544. PubMed ID: 36654520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP).
    Garvey E; Naimi B; Duffy A; Hannikainen P; Kahn C; Farquhar D; Rosen M; Rabinowitz M; Toskala E; Nyquist G
    Int Forum Allergy Rhinol; 2024 Mar; 14(3):651-659. PubMed ID: 37506043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-utility analysis of dupilumab compared with endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyps. Evaluation in Colombia, a developing country.
    Alvarez L; Querubin J; Bedoya J; Mejia A; Sánchez J
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):571-578. PubMed ID: 36976904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.
    Bachert C; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Joish VN; Chao J; Mannent LP; Amin N; Abbe A; Taniou C; Fan C; Pirozzi G; Graham NMH; Mahajan P; Staudinger H; Khan A
    Allergy; 2020 Jan; 75(1):148-157. PubMed ID: 31306495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD.
    Brkic FF; Liu DT; Klimbacher R; Campion NJ; Bartosik TJ; Vyskocil E; Stanek V; Tu A; Arnoldner T; Bangert C; Gangl K; Eckl-Dorna J; Schneider S
    Rhinology; 2023 Aug; 61(4):320-327. PubMed ID: 37515811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential nasal swab cytology represents a valuable tool for therapy monitoring but not prediction of therapy response in chronic rhinosinusitis with nasal polyps treated with Dupilumab.
    Danisman Z; Linxweiler M; Kühn JP; Linxweiler B; Solomayer EF; Wagner M; Wagenpfeil G; Schick B; Berndt S
    Front Immunol; 2023; 14():1127576. PubMed ID: 37180133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan.
    Fujieda S; Matsune S; Takeno S; Asako M; Takeuchi M; Fujita H; Takahashi Y; Amin N; Deniz Y; Rowe P; Mannent L
    Laryngoscope; 2021 Jun; 131(6):E1770-E1777. PubMed ID: 33226139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dupilumab (Dupixent
    Jansen F; Becker B; Eden JK; Breda PC; Hot A; Oqueka T; Betz CS; Hoffmann AS
    Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1741-1755. PubMed ID: 36242612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic rhinosinusitis with nasal polyps management in the age of biologics.
    Blaiss MS
    Allergy Asthma Proc; 2020 Nov; 41(6):413-419. PubMed ID: 33109306
    [No Abstract]   [Full Text] [Related]  

  • 35. A review of phase III clinical trials of US FDA-approved biologic therapies for chronic rhinosinusitis with nasal polyposis.
    Lelegren MJ; Son SY; Han JK; Lam KK
    Immunotherapy; 2022 Jun; 14(8):655-662. PubMed ID: 35510314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status.
    Fujieda S; Matsune S; Takeno S; Ohta N; Asako M; Bachert C; Inoue T; Takahashi Y; Fujita H; Deniz Y; Rowe P; Ortiz B; Li Y; Mannent LP
    Allergy; 2022 Jan; 77(1):186-196. PubMed ID: 33993501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review.
    Nitro L; Bulfamante AM; Rosso C; Saibene AM; Arnone F; Felisati G; Pipolo C
    Acta Otorhinolaryngol Ital; 2022 Jun; 42(3):199-204. PubMed ID: 35880360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologics for chronic rhinosinusitis with nasal polyps.
    Bachert C; Zhang N; Cavaliere C; Weiping W; Gevaert E; Krysko O
    J Allergy Clin Immunol; 2020 Mar; 145(3):725-739. PubMed ID: 32145872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biologics in severe uncontrolled chronic rhinosinusitis with nasal polyps: A bicentric experience.
    Bellocchi G; Loperfido A; Passali FM; Millarelli S; Velletrani G; Perla M; Di Michele L; Di Girolamo S
    Acta Biomed; 2023 Oct; 94(5):e2023227. PubMed ID: 37850768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from a National Institutes of Health-sponsored workshop.
    Roland LT; Smith TL; Schlosser RJ; Soler ZM; Peters AT; Laidlaw TM; Bleier BS; Ramakrishnan V; Toskala E; Kennedy DW; Luong AU
    Int Forum Allergy Rhinol; 2020 Sep; 10(9):1037-1042. PubMed ID: 32484603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.